AbbVie Deutschland GmbH & Co. v. Janssen Biotech, Inc., No. 13-1338 (Fed. Cir. July 1, 2014)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

AbbVie Deutschland GmbH & Co., KG, AbbVie Bior e- search Center, Inc., and AbbVie Biotechnology Ltd. ( for- merly Abbott, collectively “AbbVie”) appeal from the final judgments of the United States District Court for the District of Massachusetts in a patent infringement action and a patent interference action. In the infringement action, patent owner AbbVie sued Janssen Biotech, Inc. and Centocor Biologics, LLC (collectively “Centocor”) for infringement of claims 29, 30, and 32 and claim 64 as depending from claim 29 of U.S.